HealthQuill Novo Nordisk A/S
Denmark’s Novo Nordisk will advance its experimental drug amycretin, in both injection and oral forms, into end-stage trials in weight management based on completed clinical studies, according to a company statement.
Drugs Health Pharma

Novo Nordisk’s obesity drug to begin end-stage trials in early 2026

HQ Team July 13, 2025: Denmark’s Novo Nordisk A/S will advance its experimental drug amycretin, in both injection and oral forms, into end-stage.

Read More
Denmark’s Novo Nordisk A/S and US-based Deep Apple Therapeutics Inc. signed an $812 million agreement to develop an oral small molecule targeting cardiometabolic diseases, such as obesity.
Climate Health Research

Novo Nordisk in $812m pact with Deep Apple for oral small molecule

HQ Team June 11, 2025: Denmark’s Novo Nordisk A/S and US-based Deep Apple Therapeutics Inc. signed an $812 million agreement to develop an.

Read More